Xwell Inc XWEL

$0.53 -0.03 (-5.42%)

Valuation

Market cap
5,937,000
Revenue TTM
$29,210,000
Net income TTM
$-16,990,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-58.17%
Debt to equity
0.00

Trading

Volume
63,700
Avg volume
44,020
Day's range
$0.53 – $0.56
Shares out
10,621,000
Stochastic %K
8%
Beta
1.04
Analysts
—
Price target
$7.00

Price

Company profile

XWELL, Inc. engages in the provision of health and wellness services to travelers in the United States and internationally. It operates in three segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment provides traveler's spa services, including massage, and nail and skin care services, as well as spa and travel products. The XpresTest segment offers COVID-19 and other medical testing to the traveli...

Show more

XWELL, Inc. engages in the provision of health and wellness services to travelers in the United States and internationally. It operates in three segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment provides traveler's spa services, including massage, and nail and skin care services, as well as spa and travel products. The XpresTest segment offers COVID-19 and other medical testing to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. customs and border protection agents; aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program; and various services and support, including technical support services and advanced services. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. It offers its services through stores and kiosks, as well as online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
212 750 9595
Website
https://www.xwell.com
Address
254 West 31st Street, 11th Floor, New York, United States

Latest news

No headlines yet.